Hydralazine Associated With Reduced Therapeutic Phlebotomy Frequency in a Nationwide Cohort Study: Real-World Effectiveness for Drug Repurposing
Conclusion: Whether a repurposed drug can serve as a cytoreductive agent for patients who require phlebotomy depends on its risk–benefit balance. We suggest that hydralazine, instead of the hydralazine–valproate combination, is a reasonable alternative for patients who require regular phlebotomy.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Databases & Libraries | Drugs & Pharmacology | Health Insurance | Hydralazine | Insurance | Leukemia | Phlebotomy | Study | Thrombosis